Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 6, 2015, Pages

  Dold, Markus ^a,b   Samara, Myrto T ^a   Li, Chunbo ^c   Tardy, Magdolna ^a   Leucht, Stefan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BENPERIDOL; BROMPERIDOL; CHLORPROMAZINE; CHLORPROTHIXENE; HALOPERIDOL; LEVOMEPROMAZINE; LOXAPINE; MESORIDAZINE; PERAZINE; PROCHLORPERAZINE; THIORIDAZINE; TRIFLUOPERAZINE; NEUROLEPTIC AGENT;

AKATHISIA; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DYSKINESIA; DYSTONIA; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RIGOR; SCHIZOPHRENIA; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; ANALOGS AND DERIVATIVES; META ANALYSIS; ORAL DRUG ADMINISTRATION; PSYCHOTIC DISORDERS;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; HALOPERIDOL; HUMANS; LOXAPINE; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; TRIFLUOPERAZINE;

EID: 84955418895     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009831.pub2     Document Type: Review

References (232)

1. Abuzzahab FS, Zimmerman RL. Psychopharmacological correlates of post psychotic depression: a double-blind investigation of haloperidol vs thiothixene in outpatient schizophrenia. Journal of Clinical Psychiatry 1982;43:105-10.
2. Baastrup PC, Alhfors UG, Bjerkenstedt L, Dencker SJ, Fensbo C, Gravem A, et al. A controlled Nordic multicentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis. Acta Psychiatrica Scandinavica 1993;87:48-58.
3. Fensbo C. Zuclopenthixol acetate, haloperidol, and zuclopenthixol in the treatment of acutely psychotic patients - a controlled multicenter study [Zuclopenthixol acetat, haloperidol og zuclopenthixol i behandling af akut psykotiske patienter. En kontrolleret multicenterundersogelse]. Nordisk Psykiatrisk Tidsskrift 1990;44:295-7.
4. Bechelli LP, Ruffino-Netto A, Hetem G. A double-blind controlled trial of pipotiazine, haloperidol and placebo in recently-hospitalized acute schizophrenic patients. Brazilian Journal of Medical and Biological Research 1983;16:305-11.
5. Brannen JO, McEvoy JP, Wilson WH, Petrie WM, Ban TA, Berney SA, et al. A double-blind comparison of bromperidol and haloperidol in newly admitted schizophrenic patients. Pharmacopsychiatria 1981;14:139-40.
6. Bueno JR. A double-blind comparative clinical trial with loxapine succinate and haloperidol in the treatment of Schizophrenia [Ensaio clinico comparativo e duplo-cego com succina de loxapina e haloperidol no tratamento da esquizofrenia]. Folha Medica 1979;78:47-52.
7. Cassano GB, Castrogiovanni P, Conti L. The computer diagnosis in a multicenter study of psychoactive agents. Psychopharmacology Bulletin 1976;12:22-4.
8. Cassano GB, Castrogiovanni P, Conti L, Bonollo L. Sulpiride - an antipsychotic agent: comparative trial vs. haloperidol. Psychopharmacology Bulletin 1977;13:41-3.
9. Cassano GB, Castrogiovanni P, Conti L, Bonollo L. Sulpiride versus haloperidol in schizophrenia: a double-blind comparative trial. Current Therapy Research, Clinical and Experimental 1975;17:189-201.
10. Castrogiovanni P, Cassano GB, Conti L, Maggini C, Bonollo L, Sarteschi P. An automated diagnostic process (PDA) in clinical psychopharmacology. An exemplification of its use in a sulpiride versus haloperidol comparative trial. International Pharmacopsychiatry 1976;11:74-83.
11. Cocchi A, Fonda P, Perosino N. Droperidol: a double-blind clinical study [Droperidol: studio clinico in doppio cieco]. Rivista Sperimentale di Freniatria e Medicina Legale Delle Alienazioni Mentali 1971;95:1109-25.
12. Cocito E, Ambrosini G, Arata A, Bevilacqua P, Tortora E. Clinical evaluation in 112 psychiatric patients of a butyrophenone neuroleptic, dehydrobenzperidol (R 4749). A controlled study in 45 patients of dehydrobenzperidol versus haloperidol. Arzneimittelforschung 1970;20:1119-25.
13. Cosar B, Candansayar S, Taner E, Isik E. Comparison of efficacy of clozapine, sulpiride, chlorpromazine and haloperidol in chronic schizophrenic patients therapy. European Neuropsychopharmacology 1999;9:287.
14. Darondel A, Balthazard JC, Brun JP. A double-blind comparison between pipotiazine and haloperidol [Bilan d'une etude controlee a double insu pipotiazine versus haloperidol]. Psychologie Medicale 1981;13:171-80.
15. Denijs EL. Clinical evaluation of bromperidol versus haloperidol in psychotic patients. International Pharmacopsychiatry 1980;15:309-17.
16. Dufresne RL, Valentino D, Kass DJ. Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacology Bulletin 1993;29:249-55.
17. Engelhardt DM, Rudorfer L, Rosen B. Haloperidol and thiothixene in the long-term treatment of chronic schizophrenic outpatients in an urban community: social and vocational adjustment. Journal of Clinical Psychiatry 1978;39:834-40.
18. Escobar JI, Mann JJ, Keller J, Wilkins J, Mason B, Mills MJ. Comparison of injectable molindone and haloperidol followed by oral dosage forms in acutely ill schizophrenics. Journal of Clinical Psychiatry 1985;46:15-9.
19. Faretra G, Dooher L, Dowling J. Comparison of haloperidol and fluphenazine in disturbed children. American Journal of Psychiatry 1970;126:1670-3.
20. Fuentenebro F, Escobar JI, Keller J, Lopez de Ochoa EF, Vazquez C. Prediction of the therapeutic response to neuroleptics in schizophrenia [Prediccion de la respuesta al tratamiento neuroleptico en la esquizofrenia]. Psiquis Revista de Psiquiatria, Psicologia y Psicosomatica 1989;10:22-8.
21. Gallant DM, Bishop M, Guerrero-Figueroa R. Effects of two butyrophenone compounds on acute schizophrenic patients: speculation on the neurophysiologic sites of action. International Journal of Neuropsychiatry 1967;3(Suppl. 1):53-7.
22. Pratt JP, Bishop MP, Gallant DM. Trifluperidol and haloperidol in the treatment of acute schizophrenia. American Journal of Psychiatry 1964;121:592-4.
23. Gerlach J, Behnke K, Heltberg J, Munk-Andersen E, Nielsen H. Dogmatil and haloperidol for the treatment of schizophrenia. Double blind cross-over study of therapeutic effectiveness, side effects and plasma concentrations. [article in french]. Semaine des Hopitaux 1985;61:1309-16.
24. Gerlach J, Behnke K, Heltberg J, Munk-Anderson E, Nielsen H. Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations. British Journal of Psychiatry 1985;147:283-8.
25. Munk-Andersen E, Behnke K, Heltberg J, Nielsen H, Gerlach J. Sulpiride versus haloperidol in the treatment of schizophrenia: A brief preliminary report [article in danish]. Nordisk Psykiatrisk Tidsskrift 1984;38:223-8.
26. Munk-Andersen E, Behnke K, Heltberg J, Nielsen H, Gerlach J. Sulpiride versus haloperidol, a clinical trial in schizophrenia. A preliminary report. Acta Psychiatrica Scandinavica. Supplementum 1984;311:31-41.
27. Germana B, Rapisarda V. Clinical therapeutic experience with bromperidol - a double-blind study [Esperienze clinico terapeutiche con bromperidolo - prova in doppio cieco e in chiaro]. Rivista di Psichiatria 1990;4:233-5.
28. Giordana JY, Frenay S. Comparative study of pipotiazine (in its non-esterified form) and of haloperidol in acute or subacute psychotic states [Etude comparative de la pipothiazine (dans sa forme non esterifiee) et de l'haloperidol au cours d'etats psychotiques aigus et subaigus]. Psychologie Medicale 1984;16:1803-15.
29. Glazer WM, Hafez H. A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophrenia Research 1990;3:315-20.
30. Glazer WM, Hafez HM, Benarroche CL. Molindone and haloperidol in tardive dyskinesia. Journal of Clinical Psychiatry 1985;46:4-7.
31. Goldstein BJ, Clyde DJ. Haloperidol in controlling the symptoms of acute psychoses. Part II. A double-blind evaluation of haloperidol and trifluoperazine. Current Therapeutic Research, Clinical and Experimental 1966;8:236-40.
32. Goldstein BJ, Brauzer B, Clyde DJ, Caldwell JM. The differential prediction of response to two anti-psychotic drugs. Psychosomatics 1969;10:193-7.
33. Gowardman M, Barrer B, Brown RA. Pimozide (R6238) in chronic schizophrenia: double-blind trial. New Zealand Medical Journal 1973;78:487-91.
34. Haas S, Beckmann H. Pimozide and haloperidol in a double-blind study in acutely schizophrenic patients [Pimozid und Haloperidol im Doppelblind-Versuch bei akut schizophrenen Patienten]. Arzneimittelforschung 1982;32:888.
35. Haas S, Beckmann H. Pimozide versus Haloperidol in acute schizophrenia. A double blind controlled study. Pharmacopsychiatria 1982;15:70-4.
36. Hall WB, Vestre ND, Schiele BC, Zimmermann R. A controlled comparison of haloperidol and fluphenazine in chronic treatment-resistant schizophrenics. Diseases of the Nervous System 1968;29:405-8.
37. Heikkilä L, Laitinen J, Vartiainen H. Cis(Z)-clopenthixol and haloperidol in chronic schizophrenic patients - a double-blind clinical multicentre investigation. Acta Psychiatrica Scandinavica 1981;294(Suppl. 1):30-8.
38. Heikkilä L, Eliander H, Vartiainen H, Turunen M, Pedersen V. Zuclopenthixol and haloperidol in patients with acute psychotic states. A double-blind, multi-centre study. Current Medical Research Opinion 1992;12:594-603.
39. Hollister LE, Overall JE, Caffey E Jr, Bennett JL, Meyer F, Kimbell I Jr, et al. Controlled comparison of Haloperidol with thiopropazate in newly admitted schizophrenics. Journal of Nervous and Mental Disorders 1962;135:544-9.
40. Howard JS. Haloperidol for chronically hospitalized psychotics: a double-blind comparison with thiothixene and placebo; a follow-up open evaluation. Diseases of the Nervous System 1974;35:458-63.
41. Ito H, Anno H, Fujii Y, Hasegawa Y, Ikegami H, Ishigooka J, et al. Clinical evaluation of bromperidol, a new investigational butyrophenone derivative, in schizophrenia, a double-blind comparison of bromperidol and haloperidol. Rinsho Hyoka (Clinical Evaluation) 1985;13:105-36.
42. Itoh H. A comparison of the clinical effects of bromperidol, a new butyrophenone derivative, and haloperidol on schizophrenia using a double- blind technique. Psychopharmacology Bulletin 1985;21:120-2.
43. Kariya T, Shimazono Y, Itoh H, Mori A, Murasaki M, Sugano K, et al. A comparison of the clinical effects of timiperone, a new butyrophenone derivative, and haloperidol on schizophrenia using a double-blind technique. Journal of International Medical Research 1983;11:66-77.
44. Kariya T, Shimazono Y, Yamashita I. Comparison of clinical effects of timiperone and haloperidol on schizophrenia using double-blind technique. Seishin Igaku (Clinical Psychiatry) 1981;10:1281-301.
45. Kinon BJ, Kane JM, Chakos M, Munne R. Possible predictors of neuroleptic-resistant schizophrenic relapse - influence of negative symptoms and acute extrapyramidal side effects. Psychopharmacology Bulletin 1993;29:365-9.
46. Kinon BJ, Kane JM, Johns C, Perovich R, Ismi M, Koreen A, et al. Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacology Bulletin 1993;29:309-14.
47. Kodama H, Sarai K, Nakahara T. The clinical efficacy of bromperidol for schizophrenia: comparison with haloperidol by the double-blind method. Igaku to Yakugaku 1984;12:269-86.
48. Kurihara M, Ito H, Kato N. Clinical evaluation of clocapramine (clofekton) in schizophrenia: a double blind comparison of clocapramine, haloperidol and perphenazine. Rinsho Seishin Igaku (Japanese Journal of Clinical Psychiatry) 1983;12:519-38.
49. Luckey WT, Schiele BC. A comparison of haloperidol and trifluoperazine. (A double-blind, controlled study on chronic schizophrenic outpatients). Diseases of the Nervous System 1967;28:181-6.
50. Malfroid M, Hens L, Roosen P, Dom R. Double-blind- evaluation of bromperidol versus haloperidol treatment in chronic psychotic patients. Acta Psychiatrica Belgica 1978;78:147-54.
51. Mattke DJ, Mombour W, Glotzner FL. The assessment of neuroleptogenic extrapyramidal syndroms in psychopharmacological research [Erfassung neuroleptisch bedingter extrapyramidaler Syndrome in einem psychopharmakologischen Forschungsprojekt]. Pharmakopsychiatrie und Neuropsychopharmakologie 1975;1:36-44.
52. Mattke DJ, Wisuschil W. A method for studying pupilomotorics under the influence of neuroleptic medication [Eine Methode zur Untersuchung der Pupillomotorik unter dem Einfluss neuroleptischer Medikation]. Arzneimittelforschung 1976;26:946-50.
53. Mauri M, Cassano GB, Canova L, Cocconcelli C, Faravelli C, Kemali D, et al. Schizophrenic disorder in active phase: double-blind study between bromperidol and haloperidol [Disturbo schizofrenico in fase attiva: studio in doppia cecita tra Bromperidolo e Aloperidolo]. Giornale di Neuropsicofarmacologia 1994;16:187-93.
54. Mori A, Kazamatsuri H, Kaneno S, Kamijima K, Kariya T, Murasaki M, et al. A double-blind comparison of a new benzamide compound YM 09151 with haloperidol in the treatment of schizophrenia. Rinsho Hyoka 1989;17:349-77.
55. Nedopil N, Ruther E. Initial improvement as predictor of outcome of neuroleptic treatment. Pharmacopsychiatria 1981;14:205-7.
56. Nishikawa T, Tsuda A, Tanaka M, Hoaki Y, Koga I, Uchida Y. Prophylactic effect of neuroleptics in symptom-free schizophrenics - a comparative dose-response study of haloperidol and propericiazine. Psychopharmacology 1984;82:153-6.
57. Nishimatu O, Horigudchi J, Akita K, Nomura S, Sarai K, Kodama H. Comparison of the clinical efficacy of methylperidol (luvatren) and haloperidol for schizophrenia by the double-blind method. Seishin Igaku (Clinical Psychiatry) 1975;4:973-85.
58. O'Brien CP, DiGiacomo JN, Webb W. Management of hostile, suspicious patients - trifluoperazine versus haloperidol. Diseases of the Nervous System 1974;35:75-8.
59. Okuda O, Akaue Y, Okishio Y. The efficacy of sulpiride in the treatment of schizophrenia by the double-blind method. Japanese Pharmacology and Therapeutics [Yakuri to Chiryo] 1979;7:439-58.
60. Paprocki J, Barcala Peixoto MP, Andrade NM. A controlled double-blind comparison between loxapine and haloperidol in acute newly hospitalized schizophrenic patients. Psychopharmacology Bulletin 1976;12:32-4.
61. Parent M, Toussaint C. Flupenthixol versus haloperidol in acute psychosis. Pharmatherapeutica 1983;3:354-64.
62. Parent M, Toussaint C. Flupenthixol versus haloperidol in acute psychotic episodes [article in french]. Acta Psychiatrica Belgica 1982;82:617-31.
63. Bures E, Poldinger W. Introductory words to the exchange of results on the clinical effects of bromperidol. Results of open and double-blind research [Einleitende Worte zum Austausch der Erfahrungen über die klinische Wirkung von Bromperidol. Mitteilung über eigene Ergebnisse im offenen und Doppelblindversuch]. International Pharmacopsychiatry 1978;13:45-52.
64. Pöldinger W. Clinical experiences in an open and a double-blind trial. Acta Psychiatrica Belgica 1978;78:96-101.
65. Pöldinger W, Bures E, Haage H. Double-blind study with two butyrophenone derivatives: bromperidol vs. haloperidol. International Pharmacopsychiatry 1977;12:184-92.
66. Pool D, Bloom W, Mielke DH, Roniger JJ Jr, Gallant DM. A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Current Therapeutic Research, Clinical and Experimental 1976;19:99-104.
67. Rama Rao V, Bailey J, Bishop M, Coppen A. A clinical and pharmacodynamic evaluation of sulpiride. Psychopharmacology 1981;73:77-80.
68. Rubin R. A double-blind comparison of the onset of activity of haloperidol and trifluoperazine. Alabama Journal of Medical Sciences 1971;8:414-8.
69. Selman FB, McClure RF, Helwig H. Loxapine succinate: a double-blind comparison with haloperidol and placebo in acute schizophrenics. Current Therapeutic Research, Clinical and Experimental 1976;19:645-52.
70. Selman FB, McClure RF, Helwig H. Loxapine succinate: a double-blind comparison with haloperidol and placebo in acute schizophrenics [article in french]. Psychologie Médicale 1979;11:1533-40.
71. Serafetinides EA. Consistency and similarity of drug EEG responses in chronic schizophrenic patients. International Pharmacopsychiatry 1973;8:214-6.
72. Serafetinides EA. Voltage laterality in the EEG of psychiatric patients. Diseases of the Nervous System 1973;34:190-1.
73. Serafetinides EA, Clark ML. Psychological effects of single dose antipsychotic medication. Biological Psychiatry 1973;7:263-7.
74. Serafetinides EA, Collins S, Clark ML. Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Disease 1972;154:31-42.
75. Serafetinides EA, Willis D. A method of quantifying EEG for psychopharmacological research. International Pharmacopsychiatry 1973;8:245-7.
76. Serafetinides EA, Willis D, Clark ML. Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. II. The electroencephalographic effects of chemically unrelated antipsychotics. Journal of Nervous and Mental Disease 1972;155:366-9.
77. Shalev A, Hermesh H, Rothberg J, Munitz H. Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatrica Scandinavica 1993;87:86-91.
78. Silverstone T, Cookson J, Ball R, Chin CN, Jacobs D, Lader S, et al. The relationship of dopamine receptor blockade to clinical response in schizophrenic patients treated with pimozide or haloperidol. Journal of Psychiatric Research 1984;18:255-68.
79. Spina E, De Domenico P, Bonanzinga M, D'Agostino MA, Gitto C, Di Rosa AE, et al. A double-blind comparative study of bromperidol versus haloperidol in schizophrenic patients. New Trends in Experimental and Clinical Psychiatry 1992;7:67-71.
80. Stewart A, Lafave HG, Segovia G. Haloperidol - new addition to the drug treatment of schizophrenia. Behavioral Neuropsychiatry 1969;1:23-8.
81. Teja JS, Grey WH, Clum JM, Warren C. Tranquilizers or anti-depressants for chronic schizophrenics: a long term study. Australian and New Zealand Journal of Psychiatry 1975;9:241-7.
82. Tobin JM, Robinson GM. Double blind comparison of haloperidol and thiothixene with after care treatment evaluation in psychiatric outpatients with schizophrenia. Psychiatric Journal of the University of Ottowa 1980;5:168-74.
83. Tuason VB. A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients. Journal of Clinical Psychiatry 1986;47:126-9.
84. Ulmar G, Edler R, Hagen M. Trifluperidol vs haloperidol - a double-blind trial. Proceedings of the 17th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1990 Sep 10-14; Kyoto, Japan. 1990:296.
85. Versiani M, da Silva JA, Frota LH, Mundim FD. Double-blind comparison between loxapine and haloperidol in the treatment of adolescent schizophrenic patients. Current Therapeutic Research 1978;24:559-66.
86. Eaton EM, Busk J, Maloney MP, Sloane RB, Whipple K, White K. Hemispheric dysfunction in schizophrenia: assessment by visual perception tasks. Psychiatry Research 1979;1:325-32.
87. White K, Busk J, Eaton E, Gomez G, Razani J, Sloane RB. Dysphoric response to neuroleptics as a predictor of treatment outcome with schizophrenics. A comparative study of haloperidol versus mesoridazine. International Pharmacopsychiatry 1981;16:34-8.
88. Al Haddad MK, Kamel C, Sequeria RP, Mawgood MA. Zuclopenthixol versus haloperidol in the initial treatment of schizophrenic psychoses, affective psychoses and paranoid states: a controlled clinical trial. Arab Journal of Psychiatry 1996;7:44-54.
89. Alpert M, Pouget ER, Sison C, Yahia M, Allan E. Clinical and acoustic measures of the negative syndrome. Psychopharmacology Bulletin 1995;31:321-6.
90. Azima H, Durost H, Arthurs D. The effect of R-1625 (haloperidol) in mental syndromes: a multiblind study. American Journal of Psychiatry 1960;117:546-7.
91. Barch DM, Carter CS. Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophrenia Research 2005;77:43-58.
92. Baro F, Van Lommel R, Dom R, De Mesmaecker L. Pimozide treatment of chronic schizophrenics as compared with haloperidol and penfluridol maintenance treatment. A multidisciplinary approach. Acta Psychiatrica Belgica 1972;72:199-214.
93. Bechelli LP, Navas-Filho F. Short term double-blind trial of pipothiazine palmitate and haloperidol in the acute phase of schizophrenia. L'Encephale 1986;12:121-5.
94. Boyer P, Puech AJ. Determinants for clinical activity of neuroleptic drugs: chemical substances, doses, assessment tools [Modalities d'action clinique des neuroleptiques: substances, doses, instruments de mesure utilises]. Psychiatrie and Psychobiologie 1987;2:296-305.
95. Brook S, Berk M, Selemani S, Kolloori J, Nzo I. A randomised controlled double blind study of zuclopenthixol acetate compared to haloperidol in acute psychosis. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria. 1997.
96. Brook S, Berk M, Selemani S, Kolloori J, Nzo I. A randomized controlled double blind study of zuclopenthixol acetate compared to haloperidol in acute psychosis. Human Psychopharmacology 1998;13:17-20.
97. Chin CN, Hamid AR, Philip G, Ramlee T, Mahmud M, Zulkifli G, et al. A double-blind comparison of zuclopenthixol acetate with haloperidol in the management of acutely disturbed schizophrenics. Medical Journal of Malaysia 1998;53:365-71.
98. Classen W, Laux G. Sensorimotor and cognitive performance of schizophrenic inpatients treated with haloperidol, flupenthixol, or clozapine. Pharmacopsychiatry 1988;21:295-7.
99. Cole JO, Tsuang MM. Haloperidol in geriatrics. Psychopharmacology Bulletin 1970;6:86-8.
100. Costa AMN, De Lima MS, Faria M, Filho SR, De Oliveira IR, De Jesus Mari J. A naturalistic, 9-month follow-up, comparing olanzapine and conventional antipsychotics on sexual function and hormonal profile for males with schizophrenia. Journal of Psychopharmacology 2007;21:165-70.
101. Crow TJ, MacMillan JF, Johnson AL, Johnstone EC. A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry 1986;148:120-7.
102. MacMillan JF, Crow TJ, Johnson AL, Johnstone EC. British Journal of Psychiatry. Short-term outcome in trial entrants and trial eligible patients 1986;148:128-33.
103. Davies LM, Lewis S, Jones PB, Barnes TRE, Gaughran F, Hayhurst K, et al. Cost-effectiveness of first- v second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. British Journal of Psychiatry 2007;191:14-22.
104. de Jesus Mari J, Lima MS, Costa AN, Alexandrino N, Rodrigues-Filho S, de Oliveira IR, et al. The prevalence of tardive dyskinesia after a nine month naturalistic randomised trial comparing olanzapine with conventional treatment for schizophrenia and related disorders. European Archives of Psychiatry and Clinical Neuroscience 2004;254:356-61.
105. Digo R, Karavokyros D, Mlynarski JC. Use of a new butyrophenone in psychiatric service. Outline of a differential study [Utilisation d'une nouvelle butyrophenone dans un service psychiatrique. Esquisse d'une etude differentielle]. L'Encephale 1967;56:75-91.
106. Dubin WR, Waxman HM, Weiss KJ, Ramchandani D, Tavani-Petrone C. Rapid tranquilization: the efficacy of oral concentrate. Journal of Clinical Psychiatry 1985;46:475-8.
107. Durost H, Lee H, Arthurs D. An early evaluation of haloperidol. In: Lehmann HE, Ban TA editor(s). The Butyrophenones in Psychiatry. Quebec Psychopharmacological Research Association, 1964:70-3.
108. Ehmann TS, Delva NJ, Beninger RJ. Flupenthixol in chronic schizophrenic inpatients: a controlled comparison with haloperidol. Journal of Clinical Psychopharmacology 1987;7:173-5.
109. Eitan N, Levin Y, Ben Artzi E, Levy A, Neumann M. Effects of antipsychotic drugs on memory functions of schizophrenic patients. Acta Psychiatrica Scandinavica 1992;85:74-6.
110. Engelhardt DM, Polizos P, Waizer J, Hoffman SP. A double-blind comparison of fluphenazine and haloperidol in outpatient schizophrenic children. Journal of Autism and Childhood Schizophrenia 1973;3:128-37.
111. Fitzgerald CH. A double-blind comparison of haloperidol with perphenazine. Current Therapeutic Research 1969;11:515-9.
112. Galderisi S, Maj M, Mucci A, Bucci P, Kemali D. QEEG alpha1 changes after a single dose of high-potency neuroleptics as a predictor of short-term response to treatment in schizophrenic patients. Biological Psychiatry 1994;35:367-74.
113. Gerlach J, Simmelsgaard H. Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine. Psychopharmacology 1978;59:105-12.
114. Gillis JS. The effects of selected antipsychotic drugs of human judgment. Current Therapeutic Research, Clinical and Experimental 1977;21:224-32.
115. Harris MJ, Panton D, Caligiuri MP, Krull AJ, Tran Johnson TK, Jeste DV. High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics. Psychopharmacology Bulletin 1992;28:87-92.
116. Holden JM, Itil TM, Keskiner A. Assessment and significance of changes in laboratory values with haloperidol and fluphenazine hydrochloride therapy. Biological Psychiatry 1970;2:173-82.
117. Huang TL, Chen JF. Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan. Schizophrenia Research 2005;80:55-9.
118. Hyugano H. The clinical psychopharmacological efficacy of bromperidol for schizophrenia comparison with haloperidol by the single-blind cross-over method. Shinryo to Shinyaku 1986;21:1296-306.
119. Itil TM, Marasa J, Saletu B, Davis S, Mucciardi AN. Computerized EEG: predictor of outcome in schizophrenia. Journal of Nervous and Mental Disease 1975;160:188-203.
120. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry 2006;63:1079-87.
121. Karsten D, Kivimaki T, Linna SL, Pollari L, Turunen S. Neuroleptic treatment of oligophrenic patients. A double-blind clinical multicentre trial of cis(z)-clopenthixol and haloperidol. Acta Psychiatrica Scandinavica Supplementum 1981;294:39-45.
122. Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate. Archives of General Psychiatry 1972;27:100-3.
123. Kelwala S, Ban TA, Berney SA, Wilson WH. Rapid tranquilization - a comparative study of thiothixene and haloperidol. Progress in Neuropsychopharmacology and Biological Psychiatry 1984;8:77-83.
124. Kurt E, Akman B, Alata G, Dadelen S, Oral T. Comparison of cardiac influences of antipsychotic drugs in patients with schizophrenia [Sizofreni tanili hastalarda antipsikotik laclarin kardiyak etkilerinin karilatirilmasi]. Klinik Psikofarmakoloji Bülteni 2007;17:155-61.
125. Lamure M, Toumi M, Chabannes JP, Dansette GY, Benyaya J, Hansen K. Zuclopenthixol versus haloperidol: an observational randomised pharmacoeconomic evaluation of patients with chronic schizophrenia exhibiting acute psychosis. International Journal of Psychiatry in Clinical Practice 2003;7:177-85.
126. Lehmann HE, Ban TA, Lee H. The effectiveness of combined phenothiazine and butyrophenone treatment in chronic schizophrenic patients. Current Therapeutic Research, Clinical and Experimental 1967;9:36-7.
127. Levenson AJ, Burnett GB, Nottingham JD, Sermas CE, Thornby JI. Speed and rate of remission in acute schizophrenia: a comparison of intramuscularly administered fluphenazine HC1 with thiothixene and haloperidol. Current Therapeutic Research, Clinical and Experimental 1976;20:695-700.
128. Liu K, Lung FW. Difference in prolactin response of schizophrenic patients to equivalent doses of haloperidol, remoxipride and sulpiride. Kao Hsiung I Hsueh Ko Hsueh Tsa Chih Kaohsiung (Journal of Medical Sciences) 1996;12:685-90.
129. Lovett WC, Stokes DK, Taylor LB, Young ML, Free SM, Phelan DG. Management of behavioral symptoms in disturbed elderly patients: comparison of trifluoperazine and haloperidol. Journal of Clinical Psychiatry 1987;48:234-36.
130. Lublin H, Gerlach J, Hagert U, Meidahl B, Molbjerg C, Pedersen V, et al. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. European Neuropsychopharmacology 1991;1:541-8.
131. Malt UF, Nystad R, Bache T, Noren O, Sjaastad M, Solberg KO, et al. Effectiveness of zuclopenthixol compared with haloperidol in the treatment of behavioural disturbances in learning disabled patients. British Journal of Psychiatry 1995;166:374-7.
132. Mosolov SN, Molodetskikh AV, Eryomin AV, Graikov GM, Nourislamov SV. Effect and tolerability of clopixol and haloperidol in patients with acute symptoms of schizophrenia: comparative randomised investigation. Sotsial'naia I Klinicheskaia Psikhiatria 2000;10:47-52.
133. Nahunek K, Svestka J, Ceskova E, Rysanek R. Blind comparison of oxyprothepin and haloperidol in six-week treatment periods in schizophrenia. Activitas Nervosa Superior 1982;24:219-20.
134. Gerlach J. Tardive dyskinesia: pathophysiological mechanisms and clinical trials. L'Encephale 1988;14:227-32.
135. Nordic Dyskinesia Study Group. Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Psychopharmacology 1986;90:423-9.
136. Povlsen UJ, Noring U, Meidahl B, Korsgaard S, Waehrens J, Gerlach J. The effects of neuroleptics on tardive dyskinesias. A video-controlled, randomized study of chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden [En videokontrolleret, randomiseret undersogelse med klorprotixen, perfenazin, haloperidol og haloperidol + biperiden]. Ugeskrift for Laeger 1987;25:1682-5.
137. Onodera I, Ito K, Ito K. The double-blind comparative study of bromperidol and haloperidol in the treatment of schizophrenic inpatients. Kiso to Rinsho 1984;18:3349-71.
138. Paprocki J, Versiani M. A double-blind comparison between loxapine and haloperidol by parenteral route in acute schizophrenia. Current Therapeutic Research, Clinical and Experimental 1977;21:80-100.
139. Pedros Rosello A, Tenias JM. Neuroleptics election and clinical outcomes in acute psychosis: a comparative study of risperidone versus other neuroleptics [Eleccion de neuroleptico y respuesta clinica en psicosis aguda: un estudio comparativo de risperidona frente a otros neurolepticos]. Anales de Psiquiatria 2004;20:167-71.
140. Reimold M, Solbach C, Noda S, Schaefer JE, Bartels M, Beneke M, et al. Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology 2007;190:241-9.
141. Reznik I, Sirota P, Psych M. Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics. Journal of Clinical Psychopharmacology 2000;20:410-6.
142. Saletu B, Kufferle B, Grunberger J, Anderer P. Quantitative EEG, SPEM, and psychometric studies in schizophrenics before and during differential neuroleptic therapy. Pharmacopsychiatry 19;1986:434-7.
143. Samuels AS. A controlled study of haloperidol: the effects of small dosages. American Journal of Psychiatry 1961;11:253-4.
144. Serban G, Siegel S. Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. American Journal of Psychiatry 1984;141:1455-8.
145. Simpson GM, Angus JW, Edwards JG. A controlled study of haloperidol in chronic schizophrenia. Current Therapeutic Research, Clinical and Experimental 1967;9:407-12.
146. Simpson GM, Cooper TB, Braun GA. Further studies on the effect of butyrophenones on cholesterol synthesis in humans. Current Therapeutic Research, Clinical and Experimental 1967;9:413-8.
147. Singh MM. Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance. Diseases of the Nervous System 1976;37:191-6.
148. Singh MM. Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance. Journal of the Bronx State Hospital 1974;2:173-83.
149. Smith RC, Baumgartner R, Ravichandran GK, Mauldin M, Burd A, Vroulis G, et al. Lateral ventricular enlargement and clinical response in schizophrenia. Psychiatry Research 1985;14:241-53.
150. Stotsky BA. Relative efficacy of parenteral haloperidol and thiothixene for the emergency treatment of acutely excited and agitated patients. Diseases of the Nervous System 1977;38:967-73.
151. Su KP, Chen KP, Shen WW, Tsai SY. QTc prolongation associated with sulpiride and haloperidol use: a pilot crossover-design study. European Neuropsychopharmacology. 2000; Vol. 10(Suppl. 3):311-2.
152. Su KP, Shen WW, Chuang CL, Chen KP, Chen CC. A pilot cross-over design study on QTc interval prolongation associated with sulpiride and haloperidol. Schizophrenia Research 2002;59:93-4.
153. Taymeeyapradit U, Kuasirikul S. Comparative study of the effectiveness of zuclopenthixol acetate and haloperidol in acutely disturbed psychotic patients. Journal of the Medical Association of Thailand 2002;85:1301-8.
154. Terminska K, Mrowiec W. Comparison of influence of perazine, fluphenazine, trifluoroperazine, chloropromazine and haloperidol on primary and deficit schizophrenic symptoms in patients first hospitalized because of paranoid schizophrenia [Badanie porownawcze wplywu perazyny, flufenazyny, trifluoroperazyny, chloropromazny i haloperydolu na objawy pierwotne i deficytowe pierwszego zachorowania na schizofrenie paranoidalna]. Psychiatria Polska 1989;1:24-30.
155. van Lommel R, Baro F, Dom R. The influence of haloperidol and penfluridol on the learning capacity of the schizophrenic. Arzneimittelforschung 1974;24:1072-4.
156. van Putten T, May PR, Marder SR. Akathisia with haloperidol and thiothixene. Archives of General Psychiatry 1984;41:1036-9.
157. van Putten T, Marder SR. Low-dose treatment strategies. Journal of Clinical Psychiatry 1986;47:12-6.
158. Zuoning J, Huang SZ, Qin YF, Yamamoto M. Comparative clinical study of nemonapride, a benzamide compound with dopamine D-2-like receptor blocking activity, and haloperidol in schizophrenic patients. Research Communications in Biological Psychology and Psychiatry 1999;24:35-46.
159. Adams CE, Bergman H, Irving CB, Lawrie S. Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD003082.pub3]
160. Adams CE, Awad GA, Rathbone J, Thornley B, Soares-Weiser K. Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD000284.pub3]
161. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
162. AMDP. Das AMDP-System. Manual zur Dokumentation psychiatrischer Befunde. 8. Göttingen: Hogrefe, 2007.
163. Andreasen NC. The Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, IA: The University of Iowa, 1983.
164. Andreasen NC. Scale for the assessment of negative symptoms. British Journal of Psychiatry 1989;155:53-8.
165. Berger M. Psychische Erkrankungen. Klinik und Therapie. 2nd edition. München: Urban & Fischer, 2003.
166. Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
167. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54:405-11. [PUBMED: 10667106]
168. Carpenter WT, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681-90.
169. Chakrabarti A, Bagnall A, Chue P, Fenton M, Palaniswamy V, Wong W, et al. Loxapine for schizophrenia. Cochrane Database of Systematic Reviews 2007, Issue 10. [DOI: 10.1002/14651858.CD001943.pub2]
170. Davis JM, Garver DL. Neuroleptics: clinical use in psychiatry. In: L. Iversen, S Iversen, S. Snyder editor(s). Handbook of Psychopharmacology. New York: Plenum Press, 1978.
171. Davis JM, Barter JT, Kane JM. Antipsychotic drugs. Comprehensive Textbook of Psychiatry. Baltimore: Williams and Wilkins, 1989.
172. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
173. Der-Simonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
174. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9.
175. Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD001359.pub2]
176. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
177. Egger M, Zellweger-Zähner T, Schneider M, Junker C, Lengeler C, Antes G. Language bias in randomised controlled trials published in English and German. Lancet 1997;350:326-9.
178. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31:140-9.
179. Essali A, Al-Haj Haasan N, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD000059.pub2]
180. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller HJ, et al. World Federation of Societies of Biological Psychiatry (WFSBP) - Guidelines for biological treatment of schizophrenia, part 1: Acute treatment of schizophrenia. World Journal of Biological Psychiatry 2005;6:132-91.
181. Feighner JP, Robins E, Guze SB, Woodruff RA Jr, Winokur G, Munoz R. Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry 1972;26:57-63.
182. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59:7-10.
183. Gaebel W, Falkai P, Weinmann S. Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff, 2006.
184. Goodrich W. Rating Scale for Quantification of Psychotic Symptom Severity (RSQPSS). American Journal of Psychiatry 1953;110:334.
185. Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
186. Guy W. ECDEU Assessment Manual for Psychopharmacology (DOTES: Dosage Record and Treatment Emergent Symptom Scale). Rockville: National Institute of Mental Health, 1976.
187. Hamilton, M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960;23:56-62.
188. Hartung B, Wada M, Laux G, Leucht S. Perphenazine for schizophrenia. Cochrane Database of Systematic Reviews 2005, (1). [DOI: 10.1002/14651858.CD003443.pub2]
189. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
190. Honigfeld G, Gillis RD, Klett CJ. Nurses' observation scale for inpatient evaluation: a new scale for measuring improvement in chronic schizophrenia. Journal of Clinical Psychology 1965;21:65-71.
191. Huf W, Kalcher K, Pail G, Friedrich ME, Filzmoser P, Kasper S. Meta-analysis: fact or fiction? How to interpret meta-analyses. World Journal of Biological Psychiatry 2011;12:188-200.
192. Hunter R, Kennedy E, Song F, Gadon L, Irving CB. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI: 10.1002/14651858.CD000440]
193. Jayakody K, Gibson RC, Kumar A, Gunadasa S. Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD000525.pub3]
194. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
195. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13:261-76.
196. Kaye JA, Bradbury BD, Jick H. Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population-based observational study. British Journal of Clinical Pharmacology 2003;56:569-75.
197. Klein DF, Davis JM. Klein DF, Davis JM. Diagnosis and drug treatment of psychiatric disorders. Baltimore: Williams and Wilkins, 1969. Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore: Williams and Wilkins, 1969.
198. Koch K, Mansi K, Haynes E, Adams CE, Sampson S, Furtado VA. Trifluoperazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD010226]
199. Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clinical Pharmacokinetics 1999;37:435-56.
200. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry 2004;161:1-56.
201. Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry 2006;59:1001-5.
202. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. What does the PANSS mean?. Schizophrenia Research 2005;79:231-8.
203. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
204. Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 2006;31:2318-25.
205. Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183-91. [PUBMED: 16905632]
206. Leucht C, Kitzmantel M, Kane J, Leucht S, Chua WLLC. Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD004278.pub2]
207. Leucht S, Corves C, Arbter D, Engel R, Li C, Davis JM. A meta-analysis comparing second-generation and first-generation antipsychotics for schizophrenia. Lancet 2009;373:31-41.
208. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209-23.
209. Lohse MJ, Müller-Oerlinghausen B. Psychopharmaka. In: U. Schwabe, D. Pfaffrath editor(s). Arzneimittelverordnungsreport. Heidelberg: Springer, 2009:767-810.
210. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
211. Marvaha S, Johnson S. Schizophrenia and employment ? a review. Social Psychiatry and Psychiatric Epidemiology 2004;39:337-49.
212. Montgomery SA, Taylor P, Montgomery D. Development of a schizophrenia scale sensitive to change. Neuropsychopharmacology 1978;17:1061-2.
213. Mothi M, Sampson S. Pimozide for schizophrenia or related psychoses. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD001949.pub3]
214. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:799-812.
215. Paton C, Lelliott P, Harrington M, Okocha C, Sensky T, Duffett R. Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients. Journal of Psychopharmacology 2003;17:223-9.
216. Sampford J, Sampson S. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD010832]
217. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. The Journal of the American Medical Association 1995;273:408-12.
218. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials 2010;11:32.
219. Schünemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al. Grading Quality of Evidence and Strength of Recommendations for Diagnostic Tests and Strategies. BMJ 2008;336:1106-10.
220. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975;188:1217-9.
221. Shen X, Xia J, Adams CE. Flupenthixol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD009777.pub2]
222. Silveira da Mota Neto JI, Soares BGO, Silva de Lima M. Amisulpride for schizophrenia. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD001357]
223. Srisurapanont M, Maneeton B, Maneeton N, Lankappa S, Gandhi R. Quetiapine for schizophrenia. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD000967.pub2]
224. Tardy M, Huhn M, Kissling W, Engel RR, Leucht S. Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD009268]
225. Tardy M, Huhn M, Engel RR, Leucht S. Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 10. [DOI: 10.1002/14651858.CD009369]
226. Tardy M, Huhn M, Engel RR, Leucht S. Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 8. [DOI: 10.1002/14651858.CD009230]
227. Tardy M, Dold M, Engel RR, Leucht S. Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD009396]
228. Tardy M, Dold M, Engel RR, Leucht S. Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 9. [DOI: 10.1002/14651858.CD009227]
229. Tsuang MT. Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Archives of General Psychiatry 1978;35:153-5.
230. World Health Organization (WHO). Essential drugs. WHO Drug Information 2009;13:249-92.
231. Wing JK. A simple and reliable subclassification of chronic schizophrenia. Journal of Mental Science 1961;107:862-76.
232. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33:254-7.